Policy & Sector Insights

The Lane Report
A bill that would put the state back in charge of its Medicaid drug program has moved to the House…Read More.

Bloomberg
Independent pharmacy groups in several states are sick of the low insurance reimbursement rates that middlemen, known as pharmacy benefit managers, or PBMs, pay them after drugs are dispensed and they’re pushing for greater oversight of the drug middlemen…Read More.

STAT
A massive lawsuit over the nation’s opioid crisis has largely ignored an influential group of companies in the prescription drug business — the financial middlemen who brokered access to the powerful pills that got so many people hooked.Read More.

Kaiser Health News
Food and Drug Administration Commissioner Scott Gottlieb said he will do everything “within my lane” to combat high drug prices and that he sees drug companies “gaming the system to try to block competition” in a multitude of ways in the marketplace…Read More.

Modern Healthcare
It’s a propitious time, at least for conservatives, for Alex Azar to take the top job at HHS. …Read More.

The Hill
History will record 2017 as a transformative year in medicine. The U.S. approved the first gene therapy that modifies a patient’s blood cells to help the immune system attack an aggressive form of leukemia in children and young adults…Read More.

STAT News
WASHINGTON — As lawmakers are puzzling over the question of why so many patients are paying so much money for prescription drugs — and what to do about it — Republicans are focusing increasing scrutiny on the middlemen: pharmacy benefit managers…Read more.

Managed Care Magazine
A few months ago Linda Cahn was pondering how a retailing giant might change the current PBM business model of convoluted contract language, secret side deals, opaque pricing structures, and the like…Read more.

Berkley Research Group
Within the U.S. healthcare system, the flow of dollars in the pharmaceutical marketplace is a complex process involving a variety of stakeholders and myriad rebates, discounts, and fees…View the Report.